| RA-CAPITAL-MANAGEMENT-L-P |
RA-CAPITAL-MANAGEMENT-L-P |
80%
|
Entities affiliated with RA Capital Management, L.P., or RA Capital, purchased common stock in the Company's IPO in May 2022, the Company's 2024 Offering in February 2024, and the Company's 2025 Offe… |
| ALNY |
Alnylam Pharmaceuticals, Inc. |
72%
|
ed unintended harmful impacts. The use of certain AI technologies can also give rise to intellectual property risks, including by disclosing or otherwise compromising our confidential or proprietary … |
| ALNY |
Alnylam Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from ALNY graph: Reciprocal relationship from PEPG graph: ed unintended harmful impacts. The use of certain AI technologies can also give rise to intellectual property risks, … |
| ARWR |
Arrowhead Pharmaceuticals, Inc. |
72%
|
ed unintended harmful impacts. The use of certain AI technologies can also give rise to intellectual property risks, including by disclosing or otherwise compromising our confidential or proprietary … |
| ARWR |
Arrowhead Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from ARWR graph: Reciprocal relationship from PEPG graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from PEPG graph: Reciprocal relationship from ARWR g… |
| DSGN |
Design Therapeutics, Inc. |
72%
|
Reciprocal relationship from DSGN graph: Reciprocal relationship from PEPG graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from PEPG graph: Reciprocal relationship from DSGN g… |
| DSGN |
Design Therapeutics, Inc. |
72%
|
ed unintended harmful impacts. The use of certain AI technologies can also give rise to intellectual property risks, including by disclosing or otherwise compromising our confidential or proprietary … |
| IONS |
Ionis Pharmaceuticals, Inc. |
72%
|
ed unintended harmful impacts. The use of certain AI technologies can also give rise to intellectual property risks, including by disclosing or otherwise compromising our confidential or proprietary … |
| IONS |
Ionis Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from IONS graph: Reciprocal relationship from PEPG graph: ed unintended harmful impacts. The use of certain AI technologies can also give rise to intellectual property risks, … |
| MYGN |
Myriad Genetics, Inc. |
72%
|
ntain, defend, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. We and our licensors may not be able to obtain, maintain, or defend patent… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from PEPG graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from PEPG graph: Reciprocal relationship from MYGN g… |
| RNAM |
RNAM |
72%
|
ed unintended harmful impacts. The use of certain AI technologies can also give rise to intellectual property risks, including by disclosing or otherwise compromising our confidential or proprietary … |
| RNAM |
RNAM |
72%
|
Reciprocal relationship from RNAM graph: Reciprocal relationship from PEPG graph: ed unintended harmful impacts. The use of certain AI technologies can also give rise to intellectual property risks, … |
| SRPT |
Sarepta Therapeutics, Inc. |
72%
|
n our development efforts and have invested our research efforts to date in developing our EDO platform. Until May 2025, we had two product candidates in clinical trials —PGN-EDODM1 for DM1 and PGN-E… |
| SRPT |
Sarepta Therapeutics, Inc. |
72%
|
Reciprocal relationship from SRPT graph: Reciprocal relationship from PEPG graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from PEPG graph: n our development efforts and have … |
| TRDA |
Entrada Therapeutics, Inc. |
72%
|
ed unintended harmful impacts. The use of certain AI technologies can also give rise to intellectual property risks, including by disclosing or otherwise compromising our confidential or proprietary … |
| TRDA |
Entrada Therapeutics, Inc. |
72%
|
Reciprocal relationship from TRDA graph: Reciprocal relationship from PEPG graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from PEPG graph: ed unintended harmful impacts. The … |
| OXFORD-SCIENCE-ENTERPRISES |
OXFORD-SCIENCE-ENTERPRISES |
70%
|
Oxford Science Enterprises, or OSE, which is an affiliate of OUI, owned 7.2 % of the Company's outstanding common stock as of March 31, 2026. |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
d infrastructure are not directly tied to any one research or drug discovery program and are deployed across multiple programs. As such, we do not track internal expenses on a program-specific basis.… |
| COMPANY-INCORPORATED |
COMPANY-INCORPORATED |
62%
|
sh at beginning of period 62,062 50,969 Cash, cash equivalents and restricted cash at end of period $ 43,698 $ 45,181 Components of cash, cash equivalents and restricted cash: Cash and cash equivalen… |
| COMPANY-OXFORD-UNIVERSITY-INNOVATION-LIMITED |
COMPANY-OXFORD-UNIVERSITY-INNOVATION-LIMITED |
62%
|
sh at beginning of period 62,062 50,969 Cash, cash equivalents and restricted cash at end of period $ 43,698 $ 45,181 Components of cash, cash equivalents and restricted cash: Cash and cash equivalen… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
ngements requiring additional payments to us or additional funding could be adversely affected. In this regard, counterparties to credit agreements and arrangements with banks in receivership or othe… |
| OXFORD-UNIVERSITY-INNOVATION-LIMITED |
OXFORD-UNIVERSITY-INNOVATION-LIMITED |
62%
|
sh at beginning of period 62,062 50,969 Cash, cash equivalents and restricted cash at end of period $ 43,698 $ 45,181 Components of cash, cash equivalents and restricted cash: Cash and cash equivalen… |
| PEPGEN-LIMITED |
PEPGEN-LIMITED |
62%
|
ngements requiring additional payments to us or additional funding could be adversely affected. In this regard, counterparties to credit agreements and arrangements with banks in receivership or othe… |
| PRESENTATION-PEPGEN-INC |
PRESENTATION-PEPGEN-INC |
62%
|
sh at beginning of period 62,062 50,969 Cash, cash equivalents and restricted cash at end of period $ 43,698 $ 45,181 Components of cash, cash equivalents and restricted cash: Cash and cash equivalen… |
